BioSpace News Archive

AmerisourceBergen Corporation (NYSE: ABC) today reported that in its fiscal year 2021 first quarter ended December 31, 2020, revenue increased 9.7 percent year-over-year to $52.5 billion.

Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that the first patient has been dosed in the Phase 2 virology trial evaluating AT-527 in mild or moderate COVID-19 patients in an outpatient setting.

BioXcel Therapeutics, Inc. (“BioXcel” or the “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced that an update from its ongoing Phase 1b/2 trial of BXCL701

Fourth-Quarter 2020 Worldwide Sales Were $12.5 Billion, an Increase of 5% Fourth-Quarter 2020 GAAP Loss per Share Was $0.83, Reflecting Charges Related to Acquisitions and Intangible Asset Impairments; Fourth-Quarter Non-GAAP EPS Was $1.32 Full-Year 2020 Worldwide Sales Were $48.0 Billion, an Increase of 2%; Excluding the Impact from Foreign Exchange, Sales Grew 4%

Reports fourth quarter 2020 revenue of $8.5 million, GAAP diluted EPS of $0.05 and non-GAAP diluted EPS of $0.07 Reports combined cash and investments of $52.0 million as of December 31, 2020

Kymera Therapeutics, Inc. (NASDAQ: KYMR), a biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced that the Company will present at two upcoming investor conferences: Guggenheim Healthcare Talks 2021 Oncology Day on Thursday, February 11 at 1:30 p.m. ET

Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) today announced that Steve Hoerter, President and Chief Executive Officer, will participate in a fireside chat at the Guggenheim Healthcare Talks 2021 Idea Forum Oncology Day on February 11, 2021 at 11:00 AM ET.

The fourth quarter showed a significant increase in business activity and we returned to organic growth. We thereby achieved a new currency-adjusted sales record for the Group, along with clearly improved earnings.

Calliditas Therapeutics AB announced that the first patient has been dosed in the global open-label extension of the Phase 3 NefIgArd study.

With over 60 million surgeries carried out under anesthesia in Europe and the United States each year, RDS has developed a connected strip that facilitates the monitoring of patients at risk of post-surgical complications.